• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pixie Dust Technologies Inc.

    5/31/24 8:00:33 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PXDT alert in real time by email
    6-K 1 ea0206562-6k_pixiedust.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2024

     

    Commission File Number 001-41749

     

    PIXIE DUST TECHNOLOGIES, INC.

    (Translation of registrant’s name into English)

     

    Pixie Dust Technologies, Inc.

    2-2-1 Yaesu, Chuo-ku

    Tokyo, 104-0028, Japan

    (Address of principal executive officer)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    ☒ Form 20-F        ☐ Form 40-F

     

     

     

     

     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    On May 31, 2024, Pixie Dust Technologies, Inc. (the “Company”) reached an agreement with The Shoko Chukin Bank, Ltd. (the “Lender”) to obtain new debt financing (the “New Debt”) in the amount of one billion yen. The maturity date of New Debt is September 30, 2025. The foregoing description of the New Debt is subject to and qualified in its entirety by reference to the full text of the New Debt, a copy of which is attached hereto at Exhibit 10.1, and the terms of which are incorporated by reference.

     

    The Company previously announced on February 26, 2024 that the Company and the Lender entered into an agreement to amend that certain Loan Agreement, dated as of March 22, 2019 (the “Prior Debt”) by and between the Company and the Lender to extend the maturity date thereunder from February 29, 2024 to May 31, 2024. The Company expects to refund the Prior Debt in full in accordance with the terms and conditions of the Prior Debt. As a consequence, the Company anticipates that entry into the New Debt will have no material impact on the Company’s cash position.

     

    The Company also expects to obtain additional debt financing from other financial institutions in Japan. Once the Company has reached any agreements with such financial institutions, the Company will provide additional information to its stockholders as part of its ongoing public company reporting obligations.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    Certain statements contained in this press release are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “aim,” “objective,” “goal,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Any such forward-looking statements are subject to various risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control, including but not limited to the strength of the economy, changes to the market for securities, the effects of inflation and its associated impact on prevailing interest rates, political or financial instability, and other factors which are set forth in the Company's prospectus that forms a part of the Registration Statement on Form F-1 (File No. 333-272476), as amended, and in all filings with the SEC made by the Company subsequent to the filing thereof (including, without limitation, the Company’s most recent annual report filed under cover of Form 20-F). The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. The Company does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

     

    Exhibit Index 

     

    Exhibit No.   Document
    10.1   Loan Agreement, dated as of May 31, 2024, by and between The Shoko Chukin Bank, Ltd. and the Registrant (English translation) 
    99.1   Press release of the Registrant, dated as of May 31, 2024 

     

    1

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      PIXIE DUST TECHNOLOGIES, INC.
         
    Date: May 31, 2024 By: /s/ Yoichi Ochiai
      Name: Yoichi Ochiai
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $PXDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PXDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXDT
    SEC Filings

    View All

    SEC Form 6-K filed by Pixie Dust Technologies Inc.

    6-K - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

    11/25/24 8:00:20 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 25 filed by Pixie Dust Technologies Inc.

    25 - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

    11/4/24 4:30:02 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.

    6-K/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

    10/24/24 1:55:49 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PXDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- Pixie Dust Technologies/

    This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release. (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission. NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Te

    10/23/24 4:30:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

    NEW YORK and TOKYO, Oct. 23, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows: 1.                  Reasons for Applying for Delisting The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets an

    10/23/24 4:30:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

    NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

    8/26/24 4:15:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

    SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

    11/14/24 10:11:11 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

    SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

    11/14/24 10:08:59 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

    SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

    11/14/24 10:06:35 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PXDT
    Financials

    Live finance-specific insights

    View All

    Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

    NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

    8/26/24 4:15:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024

    NEW YORK and TOKYO, Feb. 11, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Monday, February 12, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

    2/11/24 12:48:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024

    NEW YORK and TOKYO, Feb. 6, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Tuesday, February 13, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

    2/6/24 9:00:00 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PXDT
    Leadership Updates

    Live Leadership Updates

    View All

    Pixie Dust Technologies Announces CFO Transition

    NEW YORK and TOKYO, March 13, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, announced the appointment of Nobuhiro Takagi and Nobufusa Tarumi as co-Chief Financial Officer ("co-CFO"), effective March 13, 2024. Messrs. Takagi and Tarumi succeed Mr. Mamoru Miwa, whose resignation was not the result of any disagreement or conflict with the Company, its operations, policies, or practices. The role of the Company's Chief Accounting Officer ("CAO"), previously held by Nobuhiro Takagi, will be assumed by the co-CFOs.

    3/13/24 4:05:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care